In order to carry out comprehensive analysis of TIM3 expression in patients with HNSCC at different stages of cancer progression and therapeutic regimen, we analyzed TIM3 expression in recurrent HNSCC, HNSCC postradiotherapy, and HNSCC post‐TPF chemotherapy (cisplatin, docetaxel, and fluorouracil). This evidence concerns the gene HAVCR2 and cancer.